Des suppléments de calcium et de vitamine D, ainsi que des exercices, peuvent aider.
OstéoporoseCalciumVitamine D
#3
Les inhibiteurs augmentent-ils le risque de maladies cardiaques ?
Oui, ils peuvent augmenter le risque de maladies cardiaques chez certaines patientes.
Maladies cardiaquesInhibiteurs de l'aromataseRisque
#4
Quels signes indiquent une complication grave ?
Des douleurs thoraciques, des essoufflements ou des saignements doivent être évalués immédiatement.
ComplicationsDouleurs thoraciquesEssoufflement
#5
Comment surveiller les effets à long terme ?
Des examens réguliers et des bilans de santé sont nécessaires pour surveiller les effets à long terme.
SurveillanceEffets à long termeInhibiteurs de l'aromatase
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du cancer du sein ?
Les facteurs incluent l'âge, les antécédents familiaux et les mutations génétiques.
Facteurs de risqueCancer du seinAntécédents familiaux
#2
Le surpoids est-il un facteur de risque ?
Oui, le surpoids et l'obésité augmentent le risque de cancer du sein.
SurpoidsObésitéCancer du sein
#3
Le tabagisme influence-t-il le risque ?
Oui, le tabagisme est associé à un risque accru de cancer du sein.
TabagismeRisqueCancer du sein
#4
L'âge de la première menstruation a-t-il un impact ?
Oui, une menstruation précoce augmente le risque de cancer du sein.
MenstruationRisqueCancer du sein
#5
Les traitements hormonaux augmentent-ils le risque ?
Oui, les traitements hormonaux substitutifs peuvent augmenter le risque de cancer du sein.
Traitements hormonauxRisqueCancer du sein
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'aromatase : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de l'aromatase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de l'aromatase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-14",
"dateModified": "2025-05-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'aromatase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"url": "https://questionsmedicales.fr/mesh/D065088",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"code": {
"@type": "MedicalCode",
"code": "D065088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.399.450.855"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'aromatase",
"alternateName": "Aromatase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D047072",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Suresh Thareja",
"url": "https://questionsmedicales.fr/author/Suresh%20Thareja",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda-151 001 (Punjab), India."
}
},
{
"@type": "Person",
"name": "Pooja Ratre",
"url": "https://questionsmedicales.fr/author/Pooja%20Ratre",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur-495 009 (C.G.), India."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Keerti Mishra",
"url": "https://questionsmedicales.fr/author/Keerti%20Mishra",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur-495 009 (C.G.), India."
}
},
{
"@type": "Person",
"name": "N Lynn Henry",
"url": "https://questionsmedicales.fr/author/N%20Lynn%20Henry",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Aromatase inhibitors in the pharmacotherapy of endometriosis.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37128968",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14656566.2023.2209315"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors.",
"datePublished": "2022-09-12",
"url": "https://questionsmedicales.fr/article/36132087",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/1164355"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36006499",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10549-022-06688-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature.",
"datePublished": "2023-04-13",
"url": "https://questionsmedicales.fr/article/37052869",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11912-023-01413-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37293258",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2023/3614296"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hormones, substituts d'hormones et antagonistes d'hormones",
"item": "https://questionsmedicales.fr/mesh/D006730"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antihormones",
"item": "https://questionsmedicales.fr/mesh/D006727"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs de la synthèse des stéroïdes",
"item": "https://questionsmedicales.fr/mesh/D065088"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de l'aromatase",
"item": "https://questionsmedicales.fr/mesh/D047072"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de l'aromatase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de l'aromatase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de l'aromatase",
"description": "Comment diagnostiquer un cancer du sein ?\nQuels tests pour évaluer l'efficacité des inhibiteurs ?\nQuels marqueurs tumoraux sont surveillés ?\nQuand envisager un traitement par inhibiteurs ?\nQuels examens pour détecter des métastases ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de l'aromatase",
"description": "Quels sont les effets secondaires des inhibiteurs ?\nComment reconnaître une réaction allergique ?\nQuels symptômes indiquent une progression du cancer ?\nLes inhibiteurs causent-ils des douleurs articulaires ?\nQuels symptômes nécessitent une consultation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de l'aromatase",
"description": "Comment réduire le risque de cancer du sein ?\nLes inhibiteurs sont-ils préventifs pour les femmes à risque ?\nQuel rôle joue la génétique dans le risque ?\nLes dépistages réguliers sont-ils importants ?\nComment l'alimentation influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de l'aromatase",
"description": "Comment fonctionnent les inhibiteurs de l'aromatase ?\nQuels sont les principaux inhibiteurs disponibles ?\nQuelle est la durée du traitement ?\nLes inhibiteurs sont-ils utilisés en prévention ?\nPeut-on combiner les inhibiteurs avec d'autres traitements ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de l'aromatase",
"description": "Quelles sont les complications possibles des inhibiteurs ?\nComment gérer l'ostéoporose liée au traitement ?\nLes inhibiteurs augmentent-ils le risque de maladies cardiaques ?\nQuels signes indiquent une complication grave ?\nComment surveiller les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de l'aromatase",
"description": "Quels sont les principaux facteurs de risque du cancer du sein ?\nLe surpoids est-il un facteur de risque ?\nLe tabagisme influence-t-il le risque ?\nL'âge de la première menstruation a-t-il un impact ?\nLes traitements hormonaux augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un cancer du sein ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par mammographie, échographie et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des inhibiteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont utilisés pour évaluer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CA 15-3 et l'HER2 peuvent être surveillés."
}
},
{
"@type": "Question",
"name": "Quand envisager un traitement par inhibiteurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est envisagé après un diagnostic de cancer du sein hormono-dépendant."
}
},
{
"@type": "Question",
"name": "Quels examens pour détecter des métastases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens comme le scanner et l'IRM sont utilisés pour détecter des métastases."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets incluent bouffées de chaleur, fatigue, et douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruption cutanée, démangeaisons, et gonflement."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une progression du cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une douleur accrue, une perte de poids inexpliquée et une fatigue intense peuvent indiquer une progression."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs causent-ils des douleurs articulaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires sont un effet secondaire fréquent des inhibiteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une consultation urgente ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des saignements ou des difficultés respiratoires nécessitent une consultation urgente."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancer du sein ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, faire de l'exercice et limiter l'alcool peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils préventifs pour les femmes à risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être prescrits pour réduire le risque chez les femmes à haut risque."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la génétique dans le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations génétiques comme BRCA1 et BRCA2 augmentent le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers permettent de détecter le cancer à un stade précoce."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fruits, légumes et grains entiers peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les inhibiteurs de l'aromatase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'aromatase, réduisant la production d'œstrogènes, ce qui freine la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux inhibiteurs disponibles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux incluent l'anastrozole, le létrozole et l'exémestane."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dure généralement 5 à 10 ans, selon le cas clinique."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils utilisés en prévention ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés en prévention chez les femmes à haut risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Peut-on combiner les inhibiteurs avec d'autres traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être combinés avec la chimiothérapie ou la radiothérapie selon le cas."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des inhibiteurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'ostéoporose, les maladies cardiovasculaires et les fractures."
}
},
{
"@type": "Question",
"name": "Comment gérer l'ostéoporose liée au traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments de calcium et de vitamine D, ainsi que des exercices, peuvent aider."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs augmentent-ils le risque de maladies cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de maladies cardiaques chez certaines patientes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des essoufflements ou des saignements doivent être évalués immédiatement."
}
},
{
"@type": "Question",
"name": "Comment surveiller les effets à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des bilans de santé sont nécessaires pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du cancer du sein ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les mutations génétiques."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids et l'obésité augmentent le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de cancer du sein."
}
},
{
"@type": "Question",
"name": "L'âge de la première menstruation a-t-il un impact ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une menstruation précoce augmente le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements hormonaux substitutifs peuvent augmenter le risque de cancer du sein."
}
}
]
}
]
}
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. Electronic address: yossef.lopez@iaf.inrs.ca.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada; PROTEO, the Québec Network for Research on Protein Function, Engineering, and Applications, 1045 Avenue de la Médecine, Université Laval, Québec, QC, G1V 0A6, Canada. Electronic address: nicolas.doucet@inrs.ca.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. Electronic address: thomas.sanderson@iaf.inrs.ca.
Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Endometriosis is a benign chronic inflammatory disease responsible for debilitating pain and decreased quality of life. The traditional treatment is based on estroprogestins, progestins, GnRH analogs,...
Phase I, II, III and IV trials, on the use of AIs used for the treatment of endometriosis, have been retrieved. The pharmacokinetics and pharmacodynamics of third-generation non-steroidal AIs have als...
AIs have shown good clinical efficacy in combination with hormonal therapy in disease control, and they represent a promising second-line therapy in selected patients, yet more research is needed on a...
Although acupuncture has been used in clinical practice for thousands of years, it remains a controversial treatment option to help alleviate pain in cancer patients. In this study, we analyzed publis...
Deleterious BRCA mutations confer a significant lifetime risk of breast cancer (BC) as well as contralateral BC (CBC) in patients who do not undergo prophylactic mastectomy. Prior reports have suggest...
This is a retrospective review of patients diagnosed with non-metastatic ER+ BC between 2004 and 2014 with known BRCA mutation status. Patients were followed from primary diagnosis until CBC diagnosis...
935 subjects were included in this analysis, with 53 BRCA1 mutation carriers, and 94 BRCA2 mutation carriers. Median age at diagnosis was 42.7 years. Seventy-two percent (676) received tamoxifen and 4...
This is the first report showing that AIs reduce the risk of CBC in BRCA mutation carriers. The potential role of AIs as chemoprevention should be validated in larger independent cohorts....
The study aims to review the literature regarding musculoskeletal complications of aromatase inhibitors and treatment options for these complications....
Aromatase inhibitors are common medications to treat hormone receptor-positive breast cancer in postmenopausal women and have been shown to improve survival and prevent disease recurrence. However, 20...
Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced muscu...
This study was performed in accordance with PRISMA guidelines. The literature search and data extraction from all randomized clinical trials (RCTs) were done by two independent investigators. Eligible...
Arthralgia was reported in 13.2 to 68.7% of patients receiving AIs for early-stage breast cancer, while arthralgia induced by CDK4/6 inhibitors occurred in a much lower rate [20.5-41.2%]. Bone pain (5...
CDK4/6 inhibitors might have a protective effect against joint inflammation and arthralgia occurrence. Further studies are warranted to investigate arthralgia incidence in this population....
Coumarin is a bicyclic oxygen bearing heterocyclic scaffold formed by fusion of benzene with the pyrone ring. Because of its unique physicochemical characteristics and the ease with which it may be tr...
The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM). However, its use is confounded by the occurrence of drug resistance and debilitating...
Employing patient-derived G76 (TMZ-sensitive), BT142 (TMZ-intermediately sensitive) and G43 and G75 (TMZ-resistant) GBM lines we assessed the influence of LTZ and TMZ on cell viability and neurosphere...
Co-treatment with LTZ at a non-cytotoxic concentration (40 nM) reduced TMZ IC...
LTZ increases DNA damage and synergistically enhances TMZ activity in TMZ sensitive and TMZ-resistant GBM lines. These effects are abrogated by the addition of exogenous estradiol underscoring that th...
Clinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor-positive (HR+) breast cancer. Evidence suggests that women with obesity do not obtai...
To examine the associations of body mass index (BMI) with recurrence....
The cohort study was conducted using data from the Danish Breast Cancer Group and enrolled postmenopausal women diagnosed with stage I to III HR+ breast cancer from 1998 through 2016. Data analysis wa...
BMI was classified as (1) healthy weight (18.5-24.9), (2) overweight (25.0-29.9), (3) obesity (30.0-34.9), and (4) severe obesity (≥35.0) using the World Health Organization guidelines. Healthy weight...
Follow-up began 6 months after breast cancer surgery and continued until the first event of recurrence, contralateral breast cancer, new primary malignant neoplasm, death, emigration, end of clinical ...
A total of 13 230 patients (median [IQR] age at diagnosis, 64.4 [58.6-70.2] years) with information on BMI were enrolled. There were 1587 recurrences with a median (IQR) potential estimated follow-up ...
In this study, obesity was associated with an increased risk of breast cancer recurrence among postmenopausal patients with HR+ early-stage breast cancer treated with aromatase inhibitors. Physicians ...
The aim of this study was to analyze the persistence of women on tamoxifen (TAM) and aromatase inhibitors (AIs) in Germany, and to investigate possible determinants of non-persistence....
The present retrospective cohort study was based on the IQVIA longitudinal prescription database (LRx). The study included women with an initial prescription of TAM or AIs (anastrozole, letrozole, and...
Up to 5 years after the index date, only 35.1% of AI and 32.5% of TAM patients were continuing therapy when therapy discontinuation was defined as at least 90 days without therapy. Using a 180-day the...
Overall, the present study indicates that persistence rates are low in all age groups for both TAM and AI treatment. We found several factors (e.g., physician specialty, younger age, and type of endoc...
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for e...
